Abilify

Basic Abilify Information

• INN (International Nonproprietary Name): Aripiprazole
• Brand Names Available In United Kingdom: Abilify; generic aripiprazole; LAI formulations include Abilify Maintena and Abilify Asimtufii
• ATC Code: N05AX12
• Forms & Dosages: Tablets 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg; Orally disintegrating tablets 10 mg, 15 mg; Oral solution 1 mg/mL; Injectable LAI — Maintena 300 mg/400 mg monthly, Asimtufii 720 mg every 2 months
• Manufacturers In United Kingdom: not specified
• Registration Status In United Kingdom: not specified
• OTC / Rx Classification: Prescription-only (POM)

Critical Warnings & Restrictions

Are there risks I should know about straight away?

Start aripiprazole only under a prescriber’s care.

Arrange review by a GP or specialist within 1–2 weeks after initiation or any dose change.

Obtain documented informed consent that records the risks and benefits before starting treatment.

Carers and household members should watch for sudden mood or behaviour change, suicidal thoughts, severe akathisia, allergic reactions, or signs of neuroleptic malignant syndrome.

Report suspected serious adverse reactions to the MHRA Yellow Card scheme.

Immediate Safety Actions For UK Patients

Place the following checklist in patient notes for rapid review:

• Start under prescriber: confirm prescription and consent documented.
• Review: GP/specialist check within 1–2 weeks of start or dose change.
• Monitor: mood/behaviour, suicidality, severe restlessness (akathisia), allergic signs, NMS symptoms.
• Report: submit serious events via MHRA Yellow Card.

High‑Risk Groups

Elderly patients with dementia‑related psychosis have increased mortality with antipsychotics and aripiprazole should be avoided unless no alternatives exist and close monitoring is possible.

Pregnant or breastfeeding patients should use aripiprazole only if the clinical benefit outweighs risks and with input from a specialist perinatal mental‑health or obstetric team.

Exercise caution in severe hepatic impairment and in patients with renal disease, epilepsy, diabetes or cardiovascular disease.

INN: Aripiprazole. Legal classification: Prescription‑Only Medicine (POM).

Interaction With Activities

Aripiprazole can cause dizziness, mild sedation and impaired concentration, which may affect driving and safety‑critical work.

Check fitness to drive and workplace rules before returning to safety‑critical duties.

Temporarily restrict driving or operating heavy machinery until stable on treatment and adverse effects have resolved.

Q&A — “Can I Drive After Taking It In The UK?”

Q: Can I drive after starting aripiprazole?

A: Not automatically.

Driving fitness must be assessed individually.

If you experience drowsiness, dizziness, slowed reactions or any effect on concentration, do not drive and inform your GP.

Follow DVLA guidance for medical conditions and medicines affecting driving and inform your insurer or employer if required.

Document driving advice in the patient record.

• Immediate steps for drivers: stop driving if affected.
• Notify your GP or specialist promptly.
• Do not resume driving until symptoms clear and you have professional reassurance.
• Record the advice in your clinical notes and keep a copy for insurers if needed.

Usage Basics

INN, Brand Names Available In The UK

What names might appear on your prescription or label?

INN: Aripiprazole is the active substance name used across clinical records.

Brand names used internationally and relevant to UK prescribing include Abilify for oral forms and Abilify Maintena and Abilify Asimtufii for long‑acting injectables.

Generic aripiprazole is widely available and dispensed on NHS or private prescriptions.

Available forms include tablets (2–30 mg), orodispersible tablets (10, 15 mg), an oral solution (1 mg/mL) and LAI injectables (300/400 mg monthly; 720 mg every 2 months).

• INN = active ingredient name (aripiprazole).
• Brand = trade name such as Abilify or Abilify Maintena.
• Generic = aripiprazole sold under manufacturer names (e.g. Zentiva, Teva).

Legal Classification And NHS Context

Aripiprazole is a Prescription‑Only Medicine (POM) in the UK and must be supplied against an NHS or private prescription.

Repeat prescriptions commonly use NHS repeat workflows, the Electronic Prescription Service (EPS) or specialist shared‑care agreements for LAI administration.

Community pharmacies including Boots, LloydsPharmacy, Superdrug and independent pharmacies dispense aripiprazole under valid prescriptions.

Dosing Guide

Standard Regimens (NHS‑Aligned)

What dose will a prescriber usually start with?

Schizophrenia in adults: typical starting dose 10 mg once daily; usual dose 10–15 mg daily; range up to 30 mg daily depending on response.

Bipolar I disorder (acute mania): 15 mg once daily is common.

Adjunctive treatment for major depressive disorder: low doses of 2–5 mg once daily are used.

Paediatric dosing and lower starts apply for adolescents where authorised; consult the product licence.

LAI regimens used in specialist services include Abilify Maintena 300 mg or 400 mg monthly, and Abilify Asimtufii 720 mg every 2 months for suitable patients.

Adjustments For Comorbidities And Monitoring

Start at lower doses in the elderly and in patients at higher risk of side effects.

Use caution with a history of seizures and in severe hepatic impairment; monitor clinically.

Baseline checks should include weight/BMI, blood pressure, fasting glucose and lipids, and consideration of ECG if cardiac risk is present.

When switching antipsychotics follow specialist advice on cross‑tapering or washout strategies.

Q&A — “What If I Miss A Dose?”

If you remember the missed dose the same day, take it as soon as practical.

If it is almost time for the next dose, skip the missed dose and take the next scheduled dose.

Do not double up doses to make up for a missed tablet.

For LAI injections attend the clinic for the scheduled appointment and contact your prescriber if significantly late.

• Checklist: try to take daily doses at the same time; keep clinic appointment reminders for LAI.
• Contact points: GP, psychiatric nurse, or clinic if doses are missed repeatedly.

Interaction Chart

Food, Drink And Lifestyle Interactions

Alcohol increases sedation and may worsen adverse effects; minimise or avoid alcohol while taking aripiprazole.

Caffeine can mask sedation but may increase restlessness or akathisia in some people.

Smoking does not substantially induce aripiprazole metabolism in the way it does for some other antipsychotics, but smoking cessation advice remains important for cardiovascular health.

• Avoid excess alcohol while on aripiprazole.
• Monitor for increased restlessness with high caffeine intake.
• Encourage smoking cessation support regardless of drug interactions.

Common Drug Interactions And Yellow Card Considerations

Aripiprazole is metabolised mainly by CYP3A4 and CYP2D6.

Strong CYP3A4 inhibitors (for example certain azole antifungals) and CYP2D6 inhibitors (for example fluoxetine or paroxetine) can raise aripiprazole levels and may need dose adjustment or monitoring.

Concomitant use with other drugs that prolong the QT interval increases arrhythmia risk.

Combining aripiprazole with other central nervous system depressants increases sedation risk.

Report suspected interactions or adverse reactions to the MHRA Yellow Card scheme.

User Reports & Trends

What do patients say about aripiprazole on UK forums and sites?

Reported benefits often include reduced psychotic symptoms and improved mood within 1–4 weeks for many patients.

Common adverse experiences reported include akathisia or restlessness, insomnia, nausea, dizziness and modest weight changes.

Many users on NHS.uk and Patient.info note that LAI formulations help with adherence and reduce relapse for some patients.

• Benefits: symptom reduction, improved stability for some, LAI helps adherence.
• Common Side Effects: akathisia, insomnia, nausea, dizziness, mild sedation, transient weight gain.
• Adherence Barriers: akathisia, perceived lack of benefit, appointment access for LAI.

Counselling implications: validate the patient’s experience and set realistic expectations for onset and side‑effect timelines.

Encourage reporting of side effects to the GP, pharmacist and via the MHRA Yellow Card.

Consider using a short patient survey or PROM in clinic to capture local outcomes and tailor monitoring.

Access & Purchase Options

High‑Street Pharmacies And Chains

Community pharmacies such as Boots, LloydsPharmacy, Superdrug and independent pharmacies dispense aripiprazole on NHS or private prescriptions.

Pharmacists provide counselling, repeat‑dispensing services and medicine checks.

Long‑acting injectables are normally given in clinic or under shared‑care arrangements rather than at the high‑street counter.

Online Pharmacies And NHS E‑Prescriptions — Safety Tips

The Electronic Prescription Service (EPS) is widely used across the NHS to simplify repeat prescriptions and collection.

When using online pharmacies check GPhC registration, ensure a valid UK prescription and that a contactable pharmacist is available for counselling.

Avoid unregulated overseas sellers and never buy prescription antipsychotics without a UK prescription.

In our online pharmacy, abilify is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

• Safe Purchase Checklist: confirm GPhC registration, valid UK prescription, pharmacist contact details, secure payment and UK delivery address.
• Ask the dispensing pharmacist for written information and monitoring reminders.

Mechanism & Pharmacology

Simplified Mechanism For Patients And Clinicians

How does aripiprazole work?

Aripiprazole is a partial agonist at dopamine D2 receptors and serotonin 5‑HT1A receptors, and an antagonist at 5‑HT2A receptors.

Its modulating action can reduce psychotic symptoms while typically causing lower prolactin rises than some other antipsychotics.

ATC classification: N05AX12.

Clinical Pharmacology Terms For Prescribers

Aripiprazole is absorbed orally and is metabolised primarily by CYP3A4 and CYP2D6.

Long‑acting injectable formulations provide sustained plasma levels and can improve adherence and reduce relapse in some patients.

Consider genetic variability in CYP2D6 and drug interactions that affect CYP pathways when interpreting response and side effects.

• Partial Agonist: activates a receptor but produces less effect than a full agonist.
• Antagonist: blocks receptor activity.
• LAI: long‑acting injectable formulation given at intervals to maintain steady levels.
• ATC: Anatomical Therapeutic Chemical classification code N05AX12.

Indications & Off‑Label Uses

MHRA‑Approved Uses (UK/NICE Context)

Licensed indications include schizophrenia in adults and adolescents aged 13 and over, bipolar I disorder (manic/mixed episodes), and adjunctive treatment for major depressive disorder at low doses.

LAI forms are licensed for maintenance treatment to reduce relapse.

Use NICE guidance and local formularies to guide prescribing decisions and monitoring.

Off‑Label Practices In NHS And Private Care

Off‑label uses seen in practice include treatment of irritability in autism spectrum disorders, tic disorders or Tourette’s and select refractory cases.

Off‑label prescribing should be supported by documented informed consent, rationale and specialist oversight where appropriate.

Key Clinical Findings

What does the evidence tell us recently?

Meta‑analyses and trials indicate aripiprazole is effective for positive symptoms in schizophrenia and offers a comparatively lower metabolic and prolactin burden than olanzapine and risperidone, though akathisia risk may be higher for some patients.

Long‑acting injectable formulations have been associated with improved adherence and reduced relapse rates in pragmatic observational studies.

Adjunctive use in SSRI‑resistant depression shows benefit at low doses (2–5 mg) for selected patients.

• Evidence Grade: RCTs and meta‑analyses support efficacy in schizophrenia and bipolar disorder.
• LAI Evidence: observational and pragmatic studies show adherence benefits and relapse reduction.
• Tolerability Trade‑Off: lower metabolic/prolactin impact but higher akathisia risk in some.

Align practice with NICE and local formularies and use shared decision‑making when evidence is limited.

Alternatives Matrix

Comparison Table Suggestion

Pros And Cons Checklist For Switching Or Selecting Therapy

• Assess symptom profile and which drug class best targets presenting symptoms.
• Review side‑effect trade‑offs (metabolic vs extrapyramidal effects).
• Consider comorbidities — cardiac, diabetic, seizure risk — and potential interactions.
• Consider adherence likelihood and LAI suitability.
• Factor in patient preference, cost and local formulary availability.

Common Questions

Q1: How Long Until It Works?

Many patients notice improvement in agitation or psychotic symptoms within 1–2 weeks, with full effect taking several weeks.

LAI steady state depends on formulation and loading strategy.

Q2: Will It Make Me Gain Weight?

Aripiprazole has a lower risk of weight gain than olanzapine, but modest weight change is possible; monitor weight and BMI at baseline and periodically.

Q3: Can I Stop Suddenly?

Stopping abruptly is not recommended; taper under prescriber guidance to avoid symptom recurrence or withdrawal effects.

Q4: Pregnancy/Breastfeeding?

Manage through a perinatal mental‑health team; weigh maternal relapse risk versus potential neonatal effects.

• Checklist For Reviews: Ask about adherence, side effects, driving, contraception and pregnancy plans at each review.

NHS Cost & Access Comparison Table

How much might it cost and where can you get it?

Regional differences in EPS uptake and LAI clinic availability affect access.

LAI administration may carry clinic appointment costs or resource implications.

Cost‑saving advice: request generic aripiprazole where clinically appropriate and use NHS repeat dispensing or prepayment certificates if eligible.

Registration & Regulation

MHRA Approval And Pharmacovigilance

Aripiprazole is licensed and should be supplied in line with the product SPC and local formularies.

Report serious or unexpected reactions to the MHRA Yellow Card scheme to support pharmacovigilance.

Prescribers must document consent and follow the SPC when starting or changing therapy.

NHS Prescribing Framework And Formularies

Local NHS Trust formularies and shared‑care protocols commonly govern initiation, titration and monitoring, especially for LAI use.

Primary care initiation should be supported by specialist advice for complex cases.

• Checklist For Regulatory Compliance: documented informed consent; adhere to SPC; report Yellow Card events; maintain shared‑care records.

Storage & Handling

Household Storage And Transport Advice For UK Climate

Tablets and orodispersible tablets should be stored at room temperature, ideally between 15–30°C, kept dry and in their original packaging away from children.

The oral solution should be protected from light and discarded if discoloured.

Injectable LAIs should be refrigerated prior to reconstitution and protected from freezing as per product instructions.

NHS/Pharmacy Guidance For Disposal And Clinic Handling

Return unused or expired medicines to a pharmacy for safe disposal; do not flush medicines down the toilet.

Clinics must maintain the cold‑chain for LAIs, follow manufacturer reconstitution instructions and record batch numbers and administration details in the patient record.

• Patient Checklist: keep in original box, avoid high heat, bring LAI appointment reminders when travelling, seek pharmacist advice if unsure.

Guidelines For Proper Use

UK Pharmacist Counselling Style — Key Points To Cover

Use clear, patient‑centred language about the indication, expected onset and common and serious side effects.

Explain akathisia, sedation, metabolic risk, driving advice, contraception and pregnancy considerations and alcohol avoidance.

Discuss interactions and who to contact for urgent concerns.

Provide a written leaflet, a safety card where appropriate and document counselling in the record.

NHS Patient Safety Advice & Follow‑Up Schedule

Baseline monitoring should include weight/BMI, BP, fasting glucose and lipids and EPS assessment.

Arrange review within 1–2 weeks after starting or changing dose, then follow local monitoring intervals.

For LAI patients ensure appointment reminders, adherence support and a named clinician responsible for reviews.

• Home Monitoring Checklist: daily mood and behaviour observations, note restlessness or aggression, weekly weight checks for first months, seek urgent care for severe symptoms.
• Template For Pharmacist Record: date/time of counselling, key advice given, materials provided and planned follow‑up.

Delivery Across United Kingdom